The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Pfizer and Allogene have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor...
read more
Tetra Discovery Partners announced the FDA has granted Orphan Drug Designation for BPN14770 for the treatment of Fragile X Syndrome
read more
Eisai has submitted a sNDA for priority review to the FDA for its antiepileptic drug FYCOMPA.
read more
BioMarin announced the EMA has accepted the submission of a MAA for pegvaliase.
read more
Indivior UK Limited and C4X Discovery entered into a license agreement where Indivior UK has obtained exclusive global rights to develop and ...
read more
Imprimis has secured a patent covering the company's MKO Melt compounded formulation from the USPTO.
read more
Bayer announced that its collaboration partner Loxo Oncology has completed the rolling submission of a NDA to the FDA for larotrectinib for the ...
read more
Protagonist Therapeutics announced the company is discontinuing the Phase 2b PROPEL study of PTG-100 in patients with moderate to severe ulcerative ...
read more
Processa Pharmaceuticals announced that the company has been assigned the license for CTP-499 upon Promet's exercising of the exclusive option to ...
read more
Soligenix announced the European Commission has granted orphan drug designation to the company's recombinant modified ricin toxin A-chain subunit for ...
read more
Teva Canada Limited announced that Health Canada has approved its application for CACT Methylphenidate ER tablets, the generic version of CConcerta.
read more
Wednesday, March 21, 2018
Eiger BioPharmaceuticals announced positive FDA guidance from a discussion on the HDV program in February, including agreement that a single, ...
read more
Ocugen announced positive results from its Phase 2 proof-of-concept clinical trial of OCU310, a novel combination of brimondine tartrate and a ...
read more
AbbVie in cooperation with Neurocrine Biosciences announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.
read more
Biogen announced an agreement to acquire PF-04958242 from Pfizer, a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment ...
read more